Vol 47, No 3 (2016)
Prace poglądowe / Reviews
Published online: 2016-07-01

open access

Page views 199
Article views/downloads 235
Get Citation

Connect on Social Media

Connect on Social Media

Recommendations for assessment of co-morbidities and tyrosine kinase inhibitor choice in patients suffering from chronic myeloid leukemia

Tomasz Sacha1, Sebastian Szmit2, Dorota Zozulińska-Ziółkiewicz3, Witold Prejzner4, Joanna Góra-Tybor5
DOI: 10.1016/j.achaem.2016.06.001
Acta Haematol Pol 2016;47(3):184-196.


Treatment of chronic myeloid leukemia with tyrosine kinase inhibitors (TKI) is very effective. The vast majority of patients achieve deep and long-lasting therapeutic responses including those on molecular level. Understanding the adverse effects of TKIs is of great importance during life-long therapy. The safety profile of TKI should be considered especially when used in patients suffering from various co-morbidities. In this paper, treatment recommendations for patients suffering from diabetes mellitus, atherosclerosis with circulation disturbances in peripheral arteries, congestive heart failure, pulmonary hypertension and pleural effusions are presented. Drug interactions between TKIs and medicaments used in the treatment of the above-mentioned co-morbidities are discussed.

Article available in PDF format

View PDF (Polish) Download PDF file